Professional
Added to YB: 2025-11-21
Pitch date: 2025-11-17
OMER [bullish]
Omeros Corporation
+12.78%
current return
Author Info
No bio for this author
Company Info
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
Market Cap
$602.7M
Pitch Price
$9.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.77
P/E
-4.23
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Jacob Discovery Fund New Position: Omeros Corporation
OMER (new position): Biotech w/ Narsoplimab monoclonal antibody awaiting FDA approval this year for deadly stem cell transplant clotting disorder. Strong approval odds after roller coaster development. Favorable risk/reward. Late-stage partnership talks could resolve balance sheet concerns driving discount.
Read full article (1 min)